Literature DB >> 9815531

Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage.

A K Bednarek1, A Sahin, A J Brenner, D A Johnston, C M Aldaz.   

Abstract

Telomerase activity has been implicated to be associated with most human malignant tumors, including breast cancer. To evaluate possible associations with well-known prognostic factors in breast cancer, we performed a semi-quantitative analysis of telomerase activity levels using the very sensitive PCR-mediated telomeric repeat amplification protocol. Telomerase activity was detected in 99 of 104 breast cancer samples analyzed (95.2%), whereas no activity was detected in 10 of 10 adjacent nonmalignant breast tissues. Analysis of five breast fibroadenoma samples revealed telomerase activity in one (20%). In contrast to previous observations, we observed that 100% of stage I breast tumors were positive for telomerase activity. More interestingly, we detected telomerase activity in six of six ductal carcinoma in situ samples (i.e., stage 0). In our semiquantitative analysis of levels of enzymatic activity, we found no statistically significant correlation at the P < h 0.05 level between telomerase levels and lymph node metastasis status, estrogen and progesterone receptor status, tumor size, S-phase fraction, and ploidy. The only statistically significant correlation was found with patient age (rho = -0.3; P = 0.03). We observed no statistically significant difference in the telomerase activity levels of early tumors (stages 0 and 1) versus more advanced lesions (stages II to IV). Nevertheless, stage IV tumors displayed a tendency for higher telomerase activity levels. In summary, no clear association was observed between telomerase levels and known breast cancer prognostic indicators. However, telomerase detection by the telomeric repeat amplification protocol method, due to its high sensitivity, may be of value in early breast cancer diagnosis and detection, because our data indicate that telomerase reactivation appears to constitute a relatively early event in breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815531

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Effect of antisense oligodeoxynucleotide of telomerase RNA on telomerase activity and cell apoptosis in human colon cancer.

Authors:  Ying-An Jiang; He-Sheng Luo; Li-Fang Fan; Chong-Qing Jiang; Wei-Jin Chen
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Progression of astrocytomas and meningiomas: an evaluation in vitro.

Authors:  L Maes; J P O Kalala; M Cornelissen; L de Ridder
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

3.  Telomerase activity in gestational trophoblastic disease.

Authors:  A N Cheung; D K Zhang; Y Liu; H Y Ngan; D H Shen; S W Tsao
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

4.  Human rDNA copy number is unstable in metastatic breast cancers.

Authors:  Virginia Valori; Katalin Tus; Christina Laukaitis; David T Harris; Lauren LeBeau; Keith A Maggert
Journal:  Epigenetics       Date:  2019-08-12       Impact factor: 4.528

5.  Tumor-associated antigens in breast cancer.

Authors:  Carmen Criscitiello
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

6.  Telomerase activity and cell apoptosis in colon cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide.

Authors:  Ying-An Jiang; He-Sheng Luo; You-Yuan Zhang; Li-Fang Fan; Chong-Qing Jiang; Wei-Jin Chen
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 7.  Culture models of human mammary epithelial cell transformation.

Authors:  M R Stampfer; P Yaswen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

8.  A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.

Authors:  E Raymond; D Sun; E Izbicka; G Mangold; E Silvas; B Windle; S Sharma; H Soda; R Laurence; K Davidson; D D Von Hoff
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

Review 9.  Current status of gene therapy for breast cancer: progress and challenges.

Authors:  Cian M McCrudden; Helen O McCarthy
Journal:  Appl Clin Genet       Date:  2014-11-10

Review 10.  The potential utility of telomere-related markers for cancer diagnosis.

Authors:  Christopher M Heaphy; Alan K Meeker
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.